| rosuvastatin / Generic mfg. |
ACTRN12621000785808p: A Phase 1 Study to Evaluate the Effect of Itraconazole on the
Pharmacokinetics of GS-5718 and to Evaluate the Effect of
GS-5718 on the Pharmacokinetics of Rosuvastatin in Healthy
Subjects |
|
|
| Not yet recruiting | 1 | 32 | | | Gilead Sciences, Gilead Sciences | Inflammatory Diseases | | | | |
ACTRN12621000785808: A Phase 1 Study to Evaluate the Effect of Itraconazole on the
Pharmacokinetics of GS-5718 and to Evaluate the Effect of
GS-5718 on the Pharmacokinetics of Rosuvastatin in Healthy
Subjects |
|
|
| Recruiting | 1 | 32 | | | Gilead Sciences, Gilead Sciences | Inflammatory Diseases | | | | |
ChiCTR-IPR-15007014: Effect of Rosuvastatin (10mg/d) treatment of Nonalcoholic fatty liver disease (NAFLD) patients with Metabolic Syndrome (MS) but without diabetes evaluated by 1H-MRS: Exploratory study |
|
|
| Recruiting | 1 | 20 | | rosuvastatin (10mg/d) * 52 weeks | Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences; Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, AstraZeneca Investment (China) Co., Ltd | Nonalcoholic fatty liver disease(NAFLD) | | | | |
| Completed | 1 | 48 | | oral ingestion of a single dose of rosuvastatin tablets (5mg) ;oral ingestion of a single dose of rosuvastatin tablets (10mg) ;oral ingestion of a single dose of rosuvastatin tablets (20mg) ;oral ingestion of a single dose of rosuvastatin tablets (10mg) | The Second Affiliated Hospital, School of Medicine, Zhejiang University; The Second Affiliated Hospital， School of Medicine，Zhejiang University, Zhejiang Yongning Pharmaceutical Company | Hypercholesterolemia (phase II); Phase I pharmacokinetics study（not involving disease） | | | | |
ChiCTR-TTRCC-12002290: Investigations on relations between SNPs in statin-related transporters and metabolizing enzymes and pharmacokinetics of fluvastatin, simvastatin, rosuvastatin and pitavastatin |
|
|
| Completed | 1 | 64 | | Retrospective analysis of pharmacokinetics data and collect 5ml blood for genotying ;Retrospective analysis of pharmacokinetics data and collect 5ml blood for genotying ;Retrospective analysis of pharmacokinetics data and collect 5ml blood for genotying ;Retrospective analysis of pharmacokinetics data and collect 5ml blood for genotying | The 2nd Affiliated Hospital, School of Medicine, Zhejiang University; The Second Affiliated Hospital， School of Medicine，Zhejiang University, Division of Clinical Pharmacology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University | not disease-related | | | | |
ChiCTR-RCH-12002706: Role of BCRP 421C>A and 34G>A polymorphisms on rosuvastatin pharmacokinetics in healthy Chinese males and its molecular mechanism |
|
|
| Completed | 1 | 72 | | Nil | Institute of Clinical Pharmacology, Central South University; Level of the institution：, National Natural Science Foundation of China | Hyperlipidemia | | | | |
ChiCTR-RCH-12002823: analysis ABCG2 gene methylation and exporing its effects on pharmacokinetics of rosuvastatin |
|
|
| Completed | 1 | 24 | | rosuvastatin | Institute of Clinical Pharmacology, Central South University; Institute of Clinical Pharmacology, Central South University, National Natural Science Foundation of China | Hyperlipidemia | | | | |
ChiCTR-ONC-13003007: Interactions of herbs with statin drugs and potential mediation by drug transporters |
|
|
| Not yet recruiting | 1 | 36 | | Simvastatin 20mg/ Rosuvastatin 10mg for 3 days and Green Tea Extract 400mg for 15 days | Chinese University of Hong Kong; Level of the institution：, Chinese University of Hong Kong | Healthy Volunteers | | | | |
NCT02592317: A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer |
|
|
| Recruiting | 1 | 20 | Europe, RoW | JNJ 56021927, Drug Cocktail, Pioglitazone, Rosuvastatin | Aragon Pharmaceuticals, Inc. | Prostatic Neoplasms, Castration-Resistant | 11/16 | 12/27 | | |
ChiCTR1900021628: A Drug-drug Interaction(DDI) Study Of Yimitasvir And Rosuvastatin In Healthy Male Subjects |
|
|
| Not yet recruiting | 1 | 14 | | Yimitasvir100mg+Rosuvastatin10mg | the First Hospital of Jilin University; the First Hospital of Jilin University, self-funding | chronic hepatitis C | | | | |
NCT03864042: Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors |
|
|
| Completed | 1 | 56 | Europe, Canada, US | losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil | Pfizer, Pierre Fabre Laboratories | Advanced Solid Tumors, Metastatic Melanoma | 07/22 | 05/23 | | |
NCT05594615: Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects |
|
|
| Completed | 1 | 24 | US | EDP-235, Midazolam, Rosuvastatin, Caffeine | Enanta Pharmaceuticals, Inc | COVID-19 | 11/22 | 11/22 | | |
NCT05389722: A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants |
|
|
| Completed | 1 | 24 | US | CC-92480, BMS-986348, Rifampin, Itraconazole, Digoxin, Rosuvastatin | Bristol-Myers Squibb | Healthy Volunteers | 11/22 | 11/22 | | |
NCT04887194: PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates |
|
|
| Completed | 1 | 40 | US | Sitravatinib, MGCD516, Warfarin, Coumadin, Dextromethorphan, Robitussin, Midazolam, Versed, Digoxin, LANOXICAPS, Rosuvastatin, Crestor, Nivolumab, OPDIVO | Mirati Therapeutics Inc. | Advanced Solid Tumor | 12/22 | 12/22 | | |
| Recruiting | 1 | 10 | Europe | Placebo, Ticagrelor, Rosuvastatin | Helsinki University Central Hospital, University of Helsinki | Pharmacokinetics | 12/22 | 12/22 | | |
NCT05652660: A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults |
|
|
| Completed | 1 | 12 | US | ARV-471, PF-07850327, Rosuvastatin, CRESTOR® | Pfizer, Arvinas Estrogen Receptor, Inc. | Healthy | 02/23 | 03/23 | | |
NCT05708573: Potential Drug Interaction Between ALXN2040 and Rosuvastatin |
|
|
| Completed | 1 | 20 | US | Rosuvastatin, ALXN2040 | Alexion | Healthy Participants | 03/23 | 04/23 | | |
NCT05763459: A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects |
|
|
| Completed | 1 | 12 | US | ABBV-CLS-7262 | Calico Life Sciences LLC, AbbVie | Healthy | 05/23 | 06/23 | | |
NCT05787002: A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin. |
|
|
| Completed | 1 | 16 | US | AZD0780, Rosuvastatin | AstraZeneca | Dyslipidemia | 05/23 | 05/23 | | |
NCT05789342: A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers |
|
|
| Completed | 1 | 54 | RoW | GP681, Rosuvastatin, Digoxin, Itraconazole, Oseltamivir | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Healthy Volunteers | 09/23 | 10/23 | | |
NCT05898672: A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin |
|
|
| Completed | 1 | 12 | Europe | Rosuvastatin, Nirmatrelvir/ritonavir | Pfizer | Pharmacokinetics, Healthy Volunteers | 08/23 | 08/23 | | |
NCT05954624: Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid |
|
|
| Completed | 1 | 49 | RoW | Digoxin, Rosuvastatin, ZSP1273, Itraconazole, Probenecid | Guangdong Raynovent Biotech Co., Ltd | Drug Drug Interaction | 11/23 | 11/23 | | |
NCT05788328: A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants |
|
|
| Terminated | 1 | 16 | US | Dabigatran etexilate (DE), Pradaxa, Rosuvastatin, Crestor, PF-07081532, Lotiglipron | Pfizer | Healthy | 09/23 | 09/23 | | |
NCT03720366: A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients |
|
|
| Completed | 1 | 40 | RoW | enasidenib, CC-90007, AG-221, Arm 1 probes, Arm 2 Probes, Arm 3 probes | Celgene | Leukemia, Myeloid, Acute | 09/23 | 12/23 | | |
NCT05981365: Voxelotor CYP and Transporter Cocktail Interaction Study |
|
|
| Completed | 1 | 44 | US | Voxelotor, Oxbryta, Bupropion, Wellbutrin, Repaglinide, Prandin, Flurbiprofen, Ansaid, Omeprazole, Prilosec, Midazolam, Dormicum, Metformin, Glucophage, Furosemide, Lasix, Rosuvastatin, Crestor | Pfizer | Sickle Cell Disease | 10/23 | 10/23 | | |
NCT05906836: A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants |
|
|
| Completed | 1 | 32 | US | Rosuvastatin, Selpercatinib, LY3527723, LOXO-292, Retevmo® | Eli Lilly and Company | Healthy | 10/23 | 10/23 | | |
NCT06031454: Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin |
|
|
| Completed | 1 | 56 | RoW | Midazolam, Omeprazole, Rosuvastatin, Verapamil, Rifampin, Leritrelvir | Guangdong Raynovent Biotech Co., Ltd | Drug Drug Interaction | 11/23 | 12/23 | | |
ChiCTR2300072490: A single-center, open, fixed-sequence phase I clinical study to evaluate the pharmacokinetics of multiple doses of Desidustat Tablets on a single dose of rosuvastatin calcium tablets in healthy subjects |
|
|
| Not yet recruiting | 1 | 24 | | Desidustat tablets 150 mg, D4, D6, D8, D10, administered 4 times, Bupropion hydrochloride sustained-release tablets 150 mg, D1, D10, administered twice | Henan Privince Hospital of Traditional Chinese Medicine; Kangzhe (Hunan) Pharmaceutical Co., Ltd., Sponsor | Renal anemia | | | | |
NCT06081166: A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin |
|
|
| Completed | 1 | 74 | Canada | Obicetrapib, tablets, Atorvastatin Calcium, Rosuvastatin Calcium | NewAmsterdam Pharma, Pharma Medica Research, Inc. | Healthy Volunteers | 12/23 | 01/24 | | |
NCT06191991: A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies) |
|
|
| Active, not recruiting | 1 | 27 | US | Atorvastatin, ALG-055009, Rosuvastatin | Aligos Therapeutics | Healthy Volunteers | 03/24 | 06/24 | | |
NCT06092931: A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants |
|
|
| Completed | 1 | 28 | US | DC-806, Midazolam, Repaglinide, Digoxin, Rosuvastatin | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Healthy Participants | 11/23 | 11/23 | | |
NCT06475872: Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" and "Crestor Tablet 5 mg (Rosuvastatin Calcium)" in Healthy Adult Subjects |
|
|
| Completed | 1 | 36 | RoW | Crecheck Tablet 2.5 mg, Rosuvastatin Calcium, Crestor Tablet 5 mg | Hanlim Pharm. Co., Ltd. | Primary Hypercholesterolemia, Combined Hyperlipidemia | 12/23 | 12/23 | | |
NCT06162169: A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects |
|
|
| Completed | 1 | 66 | RoW | JAB-21822, Itraconazole, Omeprazole, Midazolam , Rosuvastatin calcium and digoxin, Rifampicin | Jacobio Pharmaceuticals Co., Ltd. | Healthy Subjects | 02/24 | 02/24 | | |
ChiCTR2100048407: A randomized controlled trial of rosuvastatin in the prevention of deep vein thrombosis in total knee arthroplasty |
|
|
| Recruiting | 1 | 226 | | Fondaparinux sodium ;Rosuvastatin + fondaparinux sodium | The Third Hospital of Mianyang, Sichuan Mental Health Center; The Third Hospital of Mianyang, Science and technology project of Sichuan province | End-stage knee disease | | | | |
| Active, not recruiting | 1 | 20 | US | Rosuvastatin, Crestor, Rosuvastatin (Inhibitor arm), Cresto, Eltrombopag, Promacta | University of California, San Francisco, Food and Drug Administration (FDA) | Healthy Volunteers | 12/24 | 12/24 | | |
NCT06186622: A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants |
|
|
| Completed | 1 | 50 | US | Orforglipron, LY3502970, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, Midazolam, Sodium Bicarbonate | Eli Lilly and Company | Healthy, Obese, Overweight | 07/24 | 07/24 | | |
NCT06111521: A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants |
|
|
| Completed | 1 | 35 | US | LY3537982, Digoxin, Rosuvastatin, Midazolam | Eli Lilly and Company, Loxo Oncology, Inc. | Healthy | 04/24 | 04/24 | | |
NCT06293742: ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants |
|
|
| Completed | 1 | 48 | US | ECC5004, Midazolam, Rosuvastatin, Digoxin, Atorvastatin | Eccogene | Type 2 Diabetes Mellitus | 04/24 | 04/24 | | |
NCT06279234: A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 1 | 122 | US | Placebo, Rosuvastatin, Midazolam, Omeprazole, PF-06954522 | Pfizer | Type 2 Diabetes Mellitus (T2DM), Obesity | 12/24 | 12/24 | | |
NCT05738291: A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood |
|
|
| Completed | 1 | 67 | Europe | BI 1839100, Placebo matching BI 1839100, midazolam, digoxin, rosuvastatin | Boehringer Ingelheim | Healthy | 06/24 | 06/24 | | |
NCT05384262: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects |
|
|
| Completed | 1 | 183 | Europe, US | AZD0780, Placebo, Rosuvastatin | AstraZeneca, Parexel | Dyslipidemia | 06/24 | 06/24 | | |
NCT06329895: A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants |
|
|
| Completed | 1 | 15 | Europe | BAY2927088, Dabigatran etexilate, Rosuvastatin | Bayer | Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers | 06/24 | 06/24 | | |
NCT06105255: A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553 |
|
|
| Completed | 1 | 45 | RoW | D-1553, other | InventisBio Co., Ltd | Healthy Male | 02/24 | 02/24 | | |
NCT06348290: Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 72 | NA | JMKX001899, Itraconazole, Midazolam, Rifampin, dextromethorphan, Rosuvastatin, digoxin | Jemincare | Solid Tumor, Adult | 05/24 | 09/24 | | |
| Recruiting | 1 | 50 | US | Rosuvastatin 10mg | Children's Mercy Hospital Kansas City | Cholesterol; Lipidosis | 01/25 | 01/25 | | |
BASiC-CIC, NCT06304896: Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy |
|
|
| Not yet recruiting | 1 | 150 | RoW | Carvedilol, Carvid, Coreg, Ramipril, Tritace, Altace, Rosuvastatin, Crestor, Colchicine, Colcrys, Mitigare, Placebo | Arab Contractors Medical Centre | Chemotherapy Induced Systolic Dysfunction | 05/25 | 12/25 | | |
NCT06503679: A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants |
|
|
| Recruiting | 1 | 48 | US | LY4100511 (DC-853) Dose 1, LY4100511 (DC-853) Dose 2, LY4100511 (DC-853) Dose 3, Midazolam, Repaglinide, Digoxin, Rosuvastatin | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Healthy | 12/24 | 12/24 | | |
NCT06491550: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin in Healthy Participants |
|
|
| Recruiting | 1 | 92 | US | AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin- Part C, Rosuvastatin and AZD4144 Part C | AstraZeneca | Healthy Participants | 04/25 | 04/25 | | |
NCT06554821: A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants |
|
|
| Completed | 1 | 28 | Europe | Rosuvastatin, CRESTOR, Ticagrelor, BRILIQUE | AstraZeneca, Parexel | Healthy Participants | 10/24 | 10/24 | | |
NCT05926180: Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients With EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19) |
|
|
| Recruiting | 1 | 31 | RoW | DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin), Inapplicable | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 08/24 | 08/24 | | |
NCT06567327: A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese |
|
|
| Recruiting | 1 | 40 | US | Danuglipron, PF-06882961, Atorvastatin, Rosuvastatin | Pfizer | Obesity | 03/25 | 03/25 | | |
| Not yet recruiting | 1 | 20 | NA | Rosuvastatin, Placebo | Stanford University | Crohn's Ileocolitis, Crohn Disease | 09/27 | 09/28 | | |
NCT06601517: A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects. |
|
|
| Not yet recruiting | 1 | 30 | RoW | Repaglinide, Atorvastatin, Digoxin, Rosuvastatin, HDM1002 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Healthy Adult Subject, Overweight Subject | 02/25 | 04/25 | | |
NCT06594159: A Study of LY4065967 in Healthy Japanese Participants |
|
|
| Not yet recruiting | 1 | 69 | Japan | LY4065967, Placebo, Rosuvastatin | Eli Lilly and Company | Healthy | 03/25 | 03/25 | | |
NCT06105060: Clinical Effects of New Approach on Patients with Non-alcoholic Steatohepatitis |
|
|
| Completed | 1 | 175 | RoW | Rosuvastatin 20mg, N-acetyl cysteine, Vitamin E | Beni-Suef University | Non-alcoholic Steatohepatitis | 06/24 | 06/24 | | |
NCT05912387: Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study |
|
|
| Recruiting | 1 | 15 | US | Rosuvastatin | Stanford University | Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases | 05/25 | 12/25 | | |
ChiCTR2300075797: Effect and mechanism of Lengzhu granule on critical disease of coronary heart disease |
|
|
| Recruiting | 1 | 74 | | According to the secondary prevention of coronary heart disease, patients were given health education, adjustment of lifestyle, control of risk factors, such as smoking cessation, control of blood pressure, blood sugar, blood lipids, etc. In terms of drug selection, single anti-platelet aggregation was given: aspirin 100mg qd or clopidogrel 75mg qd or ticagrelor 90mg bid po, lipid-stabilizing plaque: atorvastatin calcium tablet 20mg qn or rosuvastatin 10mg qn. The dosage of β-blocker was determined by the patient's blood pressure and resting heart rate, and CCB/ACEI/ARB was determined by the patient's blood pressure, blood potassium and kidney function. At the same time, gastric protection drugs were given: Iprrazole or rabeprazole enteric-coated tablets 10mg qd.; Western medicine treatment plan is the same as the control group, Chinese medicine plus Lengzhu granules (vinegar Sanling formula granules 1g, specifications: 1g granules /9g decoction pieces; Vinegar Zedoary (Guangxi Zedoary) formula granules 1g, specifications: 1g granules /8g decoction pieces; Ginger formula granule 6g, specification: 0.5g granule /6g decoction piece; Jujube formula granules 3g, specifications: 2.5g granules /3g decoction pieces; Glycyrrhiza formula granules 3g, specifications: 1g granules /3g decoction pieces; Drug production Company: Jiangyin Tianjiang Pharmaceutical Co., LTD.) Water infusion, 1 dose/day; The course of treatment is 40 days. | Guangdong Provincial Hospital of Chinese Medicine Zhuhai Hospital; Guangdong Provincial Hospital of Chinese Medicine, None | Coronary heart disease | | | | |
